In IBD patients, approximately 40% have a primary non-response to tumor necrosis factor (TNF) inhibitors, and 23-46% lose response after one year [6]. In IBD patients, the partial response rate for the immunomodulator tacrolimus is 37% [7]. This evidence concerns the gene TNF and inflammatory bowel disease.